|
|
LSBC MEMBER NEWS ANNOUNCEMENTS
|
As a member benefit, LifeSciences BC publishes all our member news releases as we receive them. If you are a member and would like to have your news release published in
BioLinks, send them along to Susan Ogilvie at
sogilvie@lifesciencesbc.ca . Please include you company logo and a point of contact in the release.
Our BioLInks data shows us that we have an open rate of 39% with our member news getting the highest click - open rate. With a subscriber circulation of 4000+ readers, the data tells us the member news is a valuable read for our subscribers! So please, keep us up to date with your news - we all enjoy hearing about it!
|
|
Up
date from President & CEO Wendy Hurlburt
|
|
Wendy Hurlburt, President & CEO, LifeSciences BC
|
|
Over the past several months, we have seen how B.C. lead innovation and R&D are furthering the response to solving the COVID-19 pandemic. The momentum of the B.C. life sciences sector is evident, from the advances in research, the adoption of digital health tools, expanding capabilities in medtech, and the overall energized vitality of our biotech sector.
Our sector is attracting a lot of attention, apparent in the number of impressive, recent announcements. Last week, we had exciting news from Acuitas and their advancement in developing a Covid - 19 vaccine with Pfizer Inc. BioNTech, Abcellera and Eli Lilly (Lilly), entering into human testing also for the potential treatment of Covid-19, and today, the exciting news from Zymeworks, who signed a new agreement with Merck (news release below). We are clearly in a pivotal time, a new age of discovering innovative and better patient care outcomes, that treat a range of diseases and the world has come to our door to observe and participate.
We were fortunate to have a glimpse of this innovation during our long-running Blakes Breakfast Speaking Event Thursday morning. Dr. Mel Krajden, Medical Director at the BCCDC, generously took time to provide our community with an update on COIVD-19 and the considerable work happening at the BCCDC. (In B.C. we are so fortunate to have the BCCDC and the leadership of Dr. Krajden and his esteemed colleagues working on our behalf, during this extraordinary time). In addition, Dr. Brad Nelson, Co-Founder & CEO, Innovakine Therapeutics and Jonathan Polak, CEO, Mesentech presented. They both shared with us the ground breaking research and advancements from cell-based cancer treatments to bone disease, they are pursuing.
We have a wealth of talent, exploring great opportunities to better human health, while driving a new economy in the 21
st century. There is so much to be proud of, many accomplishments past and present, and I very much look forward to sharing all the exciting news ahead.
|
|
|
|
InMed Announces Completion of Share Consolidation
|
Trading of Consolidated Shares on TSX Expected to Begin on July 3
rd
, 2020
Vancouver, BC – June 30, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), is pleased to announce, further to its press release dated June 19
th
, 2020, that in conjunction with its application to list its common shares on the Nasdaq...
READ MORE
|
|
|
|
Canadian Firm Plays Key Role in COVID-19 Vaccine Development Project with BioNTech and Pfizer
|
July 1, 2020 – Vancouver, B.C. – Acuitas Therapeutics, a Vancouver-based biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP), is seeing its already substantial reputation as a global expert in this area go further.
READ MORE
|
|
|
|
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
|
Vancouver, BC – July 7, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that dosing of subjects has begun in its second Phase 1 clinical trial with INM-755 (“755-102-HV”).
READ MORE
|
|
|
|
Zymeworks Announces New Multispecific Antibody Collaboration with Merck
|
VANCOUVER, British Columbia, July 8, 2020, –(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.
READ MORE
|
|
|
|
Genome British Columbia Annual Report for the fiscal year 2019/2020, celebrating our 20th anniversary
|
|
|
|
entrepreneurship@UBC Lab2Launch Venture Building Program
|
entrepreneurship@UBC propels UBC innovations out into the world through venture creation, cultivating real world intrapreneurial and entrepreneurial leadership. Spanning ideation to launch to funding, the program connects UBC students, alumni, researchers, faculty and staff with industry experts to move their ideas and innovations to impact.
READ MORE
|
|
 |
PHEMI Systems provides a NSA-grade privacy, security, governance, and data management system for Microsoft Azure.
PHEMI’s
Data Privacy Manager
software is easy to deploy and manage, connects to hundreds of data sources, and integrates with most popular data science and business analysis tools.
|
|
|
|
Corus Product Design is a Product Development Consulting company. They can transform your ideas into a product that you can start selling. With senior hardware, mechanical and software engineers to guide you in each step of the Product Development journey.
|
|
|
|
Community - Sector Interest
|
|
|
|
Biotech blind spot: How Canada’s big investors missed the boom happening right now
|
Lloyd Segal made history two weeks ago, leading the biggest initial public offering ever by a Canadian biotechnology startup. His Montreal-based cancer drug developer, Repare Therapeutics, raised US$253-million and during its first day of trading on the Nasdaq the stock soared by more than 50 per cent, giving the company a valuation of more than US$1-billion.
READ MORE
|
|
|
|
Federal government invests $40M in Mitacs to create 5,000 new internships
|
Investment also expands student and industry eligibilities for new partnership opportunities
Ottawa, ON — Today the Government of Canada announced a $40 million investment in the future of Canadian innovation that will support students through Mitacs internships. The funding will provide 5,000 new internship opportunities for college and university students across Canada.
READ MORE
|
|
|
|
Ali Ardakani of Novateur Ventures: How We Plan To Rebuild In The Post COVID Economy
|
Adaptation is the key to success. Seek opportunities during the Covid-19 times to advance your healthcare innovation. This is something that nature does well, and that we should learn from: rapid development to new information and the integration of that wisdom to respond with collective intelligence in the future.
READ MORE
|
|
|
|
From Wine Making to Life Saving, Barrelwise to Produce Decontamination Oven
|
Vancouver’s
BarrelWise
develops and manufactures a barrel management system that helps winemakers protect and enhance the quality of their wines by mitigating the risks of contamination in the barrel-aging process.
READ MORE
|
|
|
|
Stronger Together’ featuring Alison Orth of Clinical Trials BC
|
Here is the most recent edition of SPORCast, a Canadian show on research with the objective to improve health care and support patient oriented research. The broadcast interview focuses on questions and responses to Clinical Trials BC on working with partners and participants in a collaborative approach.
WATCH HERE
|
|
|
|
Update: Student Work Placement Program now open to healthcare placements
|
The Student Work Placement Program is now accepting applications for healthcare placements. Canada’s healthcare industry has a growing need to produce job-ready healthcare workers. There are 1,500 open spots available in 2020-21.
WEBSITE
|
|
|
|
Posting A JOB on the LSBC Website
|
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's
The Petri Dish
After your first five reposts, you will also receive 25% off all job postings on
The Petri Dish
. Want more info?
CONTACT: Sue Callaghan -
talent@lifesciencesbc.ca
|
|
|
|
Membership Benefits Program
COST SAVINGS FOR OUR MEMBERS
As a LifeSciences BC member, organizations and their employees can benefit from significant savings on a range of business and personal services, thanks to our Membership Benefits Program partnerships. You can locate the cost savings program suited to you needs
here
.
|
|
|
|
|
|
|
